VKTX
The maintenance phase gets its moment
Viking Therapeutics is back with more VK2735 data, and the market clearly liked what it saw. In the company’s maintenance trial, patients who switched from the induction phase to reduced subcutaneous dosing kept most of their weight loss, with biweekly dosing preserving up to 97% of the benefit and monthly dosing holding onto up to 90%.
Why investors care
That matters because obesity drugs aren’t just about getting the scale moving once — they’ve got to keep working without turning patients into full-time pharmacy regulars. A drug that can support less frequent maintenance dosing could have an edge on convenience, durability, and maybe even manufacturing economics down the road.
The good, the bad, and the tolerability
The other headline here: safety looked pretty manageable. GI side effects like nausea, vomiting, diarrhea, and constipation were described as comparable to placebo during the maintenance window, and discontinuations stayed low.
Big picture
Viking’s stock jumped hard on the news, which is basically the market saying, “Show us more obesity data and we’ll keep paying attention.” The next shoe to drop is whether the company can translate this into an oral maintenance regimen — because in this race, everyone wants the drug that works and is easy enough to live with.